Our Services
Medical Information
Helpful Resources
Published on: 5/21/2026
Patients often experience a reduction in itching and fewer hives within 1 to 2 weeks after starting Xolair, with about half seeing significant relief by Week 4 and most achieving optimal control by 2 to 3 months. Response speed can vary based on factors like baseline IgE levels, symptom severity, body weight, and adherence to therapy.
See below for details on dosing steps, monitoring schedules, safety precautions, and next step options to guide your treatment journey.
Chronic hives (urticaria) can be frustrating, persistent, and hard to control. Xolair (omalizumab) is a biologic therapy approved for chronic spontaneous urticaria in patients 12 years and older who don't get relief from standard antihistamines. If you're asking how fast does Xolair work for hives, understanding the science, real-world timelines, and practical steps can help set expectations and guide your treatment journey.
Xolair is a monoclonal antibody that targets immunoglobulin E (IgE). In many cases of chronic hives, patients have elevated or dysregulated IgE activity, which drives mast cell activation, histamine release, and the itching, redness, and welts you see on the skin.
Clinical trials (ASTERIA I, ASTERIA II, GLACIAL) and real-world studies help us understand when patients may notice relief. Individual responses vary, but here's a general, science-backed timeline:
Week 0 (First Dose):
You'll receive your first subcutaneous injection (usually 150 mg or 300 mg). There's no immediate skin-clearing effect, but IgE levels begin to drop within hours to days.
Week 1–2:
Some patients report reduced itch or fewer hives as early as 1 week after the first dose. In pivotal trials, roughly 30%–50% showed measurable symptom improvement by Week 2.
Week 4:
Around half of patients experience a significant reduction in hives and itching by the end of Month 1. You may notice smaller, less frequent flare-ups.
Weeks 8–12:
The majority of responders achieve their best control between 2–3 months. It's common to see 60%–75% reduction in hive counts and itch severity by Week 12.
Beyond Week 12:
Continued therapy every 4 weeks often leads to further improvement or stabilization. Some patients become virtually symptom-free; others may need combination treatments (e.g., antihistamines, leukotriene modifiers).
Several variables affect how fast Xolair works for hives:
Consult a Specialist
An allergist, immunologist, or dermatologist experienced with urticaria will confirm chronic spontaneous urticaria, rule out triggers, and review your antihistamine history.
Baseline Evaluation
Blood tests (including total IgE) and a symptom diary help set benchmarks. Your doctor may use the Urticaria Activity Score over 7 days (UAS7) to quantify severity.
Determine Dosage
Administration
Track Your Progress
Xolair is generally well tolerated. Common side effects include:
Rare but serious risks:
Always report new or worsening symptoms to your healthcare provider immediately.
These could signal anaphylaxis or another serious reaction. In those cases, seek emergency care or call your local emergency number.
If you're experiencing persistent welts, itching, or skin reactions and want to better understand whether your symptoms align with chronic hives before your specialist appointment, try Ubie's free Hives (Urticaria) symptom checker—it takes just a few minutes and can help you prepare more informed questions for your healthcare provider.
Every patient's journey is unique. If you're considering Xolair or already on therapy, keep detailed symptom logs and maintain regular contact with your specialist. And remember, if you experience any life‐threatening or serious symptoms, speak to a doctor or seek emergency medical care right away.
(References)
* Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013 Mar 7;368(10):924-30.
* Saini SS, D'Amico S, Lim N, et al. Omalizumab for chronic spontaneous urticaria: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol Pract. 2019 Mar-Apr;7(3):958-969.e6.
* Finlay AY, Kaplan AP, Weller K, et al. The effect of omalizumab on early treatment response in patients with chronic spontaneous urticaria. J Dermatolog Treat. 2018 Feb;29(1):72-79.
* Sussman G, Hébert J, Gulliver W, et al. Omalizumab for the treatment of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study (GLACIAL). J Allergy Clin Immunol. 2014 Mar;133(3):790-797.
* Staubach P, Metz M, Chapman-Rothe N, et al. Omalizumab in patients with chronic spontaneous urticaria refractory to H1-antihistamines: a 12-week open-label, multicentre study evaluating early response and safety. J Eur Acad Dermatol Venereol. 2016 Jan;30(1):153-6.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.